VJOncology is committed to improving our service to you

ESMO Breast 2020 | Effects of BMI on PFS in the MONARCH 1 and MONARCH 2 trial

VJOncology is committed to improving our service to you

Evandro de Azambuja

Evandro de Azambuja, MD, PhD, of the Institut Jules Bordet, Brussels, Belgium, reports small decreases in PFS for obese patients treated with CDK4/6 inhibitors and endocrine therapy in the MONARCH 1 (NCT02102490) and MONARCH 2 (NCT02107703) trials. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter